Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jan 11. doi: 10.1038/s41375-018-0351-2. [Epub ahead of print]

PMID:
30635634
2.

PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age-related clonal hematopoiesis and myeloid neoplasia.

Chase A, Pellagatti A, Singh S, Score J, Tapper WJ, Lin F, Hoade Y, Bryant C, Trim N, Yip BH, Zoi K, Rasi C, Forsberg LA, Dumanski JP, Boultwood J, Cross NCP.

Leukemia. 2018 Dec 20. doi: 10.1038/s41375-018-0340-5. [Epub ahead of print]

PMID:
30573780
3.

Application of induced pluripotent stem cell technology for the investigation of hematological disorders.

Dolatshad H, Tatwavedi D, Ahmed D, Tegethoff JF, Boultwood J, Pellagatti A.

Adv Biol Regul. 2019 Jan;71:19-33. doi: 10.1016/j.jbior.2018.10.001. Epub 2018 Oct 10. Review.

PMID:
30341008
4.

Cell-specific proteome analyses of human bone marrow reveal molecular features of age-dependent functional decline.

Hennrich ML, Romanov N, Horn P, Jaeger S, Eckstein V, Steeples V, Ye F, Ding X, Poisa-Beiro L, Lai MC, Lang B, Boultwood J, Luft T, Zaugg JB, Pellagatti A, Bork P, Aloy P, Gavin AC, Ho AD.

Nat Commun. 2018 Oct 1;9(1):4004. doi: 10.1038/s41467-018-06353-4.

5.

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.

Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya S, Lopez R, Pradhan K, Giricz O, Ravipati G, Wong LF, Cole S, Bhagat TD, Feld J, Dhar Y, Bartenstein M, Thiruthuvanathan VJ, Wickrema A, Ye BH, Frank DA, Pellagatti A, Boultwood J, Zhou T, Kim Y, MacLeod AR, Epling-Burnette PK, Ye M, McCoon P, Woessner R, Steidl U, Will B, Verma A.

J Clin Invest. 2018 Dec 3;128(12):5479-5488. doi: 10.1172/JCI120156. Epub 2018 Nov 5.

6.

SIRT1 Activation Disrupts Maintenance of Myelodysplastic Syndrome Stem and Progenitor Cells by Restoring TET2 Function.

Sun J, He X, Zhu Y, Ding Z, Dong H, Feng Y, Du J, Wang H, Wu X, Zhang L, Yu X, Lin A, McDonald T, Zhao D, Wu H, Hua WK, Zhang B, Feng L, Tohyama K, Bhatia R, Oberdoerffer P, Chung YJ, Aplan PD, Boultwood J, Pellagatti A, Khaled S, Kortylewski M, Pichiorri F, Kuo YH, Carlesso N, Marcucci G, Jin H, Li L.

Cell Stem Cell. 2018 Sep 6;23(3):355-369.e9. doi: 10.1016/j.stem.2018.07.018. Epub 2018 Aug 23.

PMID:
30146412
7.

Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations.

Pellagatti A, Armstrong RN, Steeples V, Sharma E, Repapi E, Singh S, Sanchi A, Radujkovic A, Horn P, Dolatshad H, Roy S, Broxholme J, Lockstone H, Taylor S, Giagounidis A, Vyas P, Schuh A, Hamblin A, Papaemmanuil E, Killick S, Malcovati L, Hennrich ML, Gavin AC, Ho AD, Luft T, Hellström-Lindberg E, Cazzola M, Smith CWJ, Smith S, Boultwood J.

Blood. 2018 Sep 20;132(12):1225-1240. doi: 10.1182/blood-2018-04-843771. Epub 2018 Jun 21.

PMID:
29930011
8.

L-leucine increases translation of RPS14 and LARP1 in erythroblasts from del(5q) myelodysplastic syndrome patients.

Bello E, Kerry J, Singh S, Yip BH, Kušec R, Killick S, Raynaud S, Boultwood J, Pellagatti A.

Haematologica. 2018 Nov;103(11):e496-e500. doi: 10.3324/haematol.2018.190447. Epub 2018 Jun 14. No abstract available.

9.

Gene expression and risk of leukemic transformation in myelodysplasia.

Shiozawa Y, Malcovati L, Gallì A, Pellagatti A, Karimi M, Sato-Otsubo A, Sato Y, Suzuki H, Yoshizato T, Yoshida K, Shiraishi Y, Chiba K, Makishima H, Boultwood J, Hellström-Lindberg E, Miyano S, Cazzola M, Ogawa S.

Blood. 2017 Dec 14;130(24):2642-2653. doi: 10.1182/blood-2017-05-783050. Epub 2017 Nov 2. Erratum in: Blood. 2018 Aug 23;132(8):869-875.

10.

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.

Armstrong RN, Steeples V, Singh S, Sanchi A, Boultwood J, Pellagatti A.

Adv Biol Regul. 2018 Jan;67:13-29. doi: 10.1016/j.jbior.2017.09.008. Epub 2017 Sep 22. Review.

PMID:
28986033
11.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96202. Epub 2017 Sep 1. No abstract available.

12.

Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes.

Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, Woll PS, Richards LA, Knezevic K, Chandrakanthan V, Thoms JAI, Tursky ML, Huang Y, Ali Z, Olivier J, Galbraith S, Kulasekararaj AG, Tobiasson M, Karimi M, Pellagatti A, Wilson SR, Lindeman R, Young B, Ramakrishna R, Arthur C, Stark R, Crispin P, Curnow J, Warburton P, Roncolato F, Boultwood J, Lynch K, Jacobsen SEW, Mufti GJ, Hellstrom-Lindberg E, Wilkins MR, MacKenzie KL, Wong JWH, Campbell PJ, Pimanda JE.

Cell Rep. 2017 Jul 18;20(3):572-585. doi: 10.1016/j.celrep.2017.06.067.

13.

Epigenetically Aberrant Stroma in MDS Propagates Disease via Wnt/β-Catenin Activation.

Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes AM, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM, Mukherjee S, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A.

Cancer Res. 2017 Sep 15;77(18):4846-4857. doi: 10.1158/0008-5472.CAN-17-0282. Epub 2017 Jul 6.

14.

The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.

Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J.

J Clin Invest. 2017 Jun 1;127(6):2206-2221. doi: 10.1172/JCI91363. Epub 2017 Apr 24. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3557.

15.

Recurrent genetic defects on chromosome 5q in myeloid neoplasms.

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP.

Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130.

16.

Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations.

Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boultwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E.

Haematologica. 2017 Mar;102(3):498-508. doi: 10.3324/haematol.2016.152025. Epub 2016 Nov 24.

17.

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.

Pellagatti A, Boultwood J.

Adv Biol Regul. 2017 Jan;63:59-70. doi: 10.1016/j.jbior.2016.08.001. Epub 2016 Aug 21. Review.

PMID:
27639445
18.

Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S, Bhagat T, Bhattacharyya S, Assal A, Shastri A, Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A.

Cancer Res. 2016 Aug 15;76(16):4841-4849. doi: 10.1158/0008-5472.CAN-15-3062. Epub 2016 Jun 10.

19.

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

Dolatshad H, Pellagatti A, Liberante FG, Llorian M, Repapi E, Steeples V, Roy S, Scifo L, Armstrong RN, Shaw J, Yip BH, Killick S, Kušec R, Taylor S, Mills KI, Savage KI, Smith CW, Boultwood J.

Leukemia. 2016 Dec;30(12):2322-2331. doi: 10.1038/leu.2016.149. Epub 2016 May 23.

20.

Expression of CDKN1C in the bone marrow of patients with myelodysplastic syndrome and secondary acute myeloid leukemia is associated with poor survival after conventional chemotherapy.

Radujkovic A, Dietrich S, Andrulis M, Benner A, Longerich T, Pellagatti A, Nanda K, Giese T, Germing U, Baldus S, Boultwood J, Ho AD, Dreger P, Luft T.

Int J Cancer. 2016 Sep 15;139(6):1402-13. doi: 10.1002/ijc.30181. Epub 2016 Jun 3.

21.

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome.

Botezatu L, Michel LC, Makishima H, Schroeder T, Germing U, Haas R, van der Reijden B, Marneth AE, Bergevoet SM, Jansen JH, Przychodzen B, Wlodarski M, Niemeyer C, Platzbecker U, Ehninger G, Unnikrishnan A, Beck D, Pimanda J, Hellström-Lindberg E, Malcovati L, Boultwood J, Pellagatti A, Papaemmanuil E, Le Coutre P, Kaeda J, Opalka B, Möröy T, Dührsen U, Maciejewski J, Khandanpour C.

Exp Hematol. 2016 Jul;44(7):590-595.e1. doi: 10.1016/j.exphem.2016.04.001. Epub 2016 Apr 11.

22.

Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.

Yip BH, Dolatshad H, Roy S, Pellagatti A, Boultwood J.

Curr Pharm Des. 2016;22(16):2333-44. Review.

PMID:
26916023
23.

The Effects of Severe Hypoxia on Glycolytic Flux and Enzyme Activity in a Model of Solid Tumors.

Smith H, Board M, Pellagatti A, Turley H, Boultwood J, Callaghan R.

J Cell Biochem. 2016 Aug;117(8):1890-901. doi: 10.1002/jcb.25488. Epub 2016 Feb 2.

PMID:
26755257
24.

Clinical associations of CSNK1A1 mutation in myelodysplastic syndrome.

Boultwood J, Pellagatti A.

Lancet Haematol. 2015 May;2(5):e182-3. doi: 10.1016/S2352-3026(15)00070-8. Epub 2015 May 6. No abstract available.

PMID:
26688092
25.

ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.

Valletta S, Dolatshad H, Bartenstein M, Yip BH, Bello E, Gordon S, Yu Y, Shaw J, Roy S, Scifo L, Schuh A, Pellagatti A, Fulga TA, Verma A, Boultwood J.

Oncotarget. 2015 Dec 29;6(42):44061-71. doi: 10.18632/oncotarget.6392.

26.

Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes.

Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw KL, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau MM, Steidl U, List AF, Evans T, Verma A, Wickrema A.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6359-68. doi: 10.1073/pnas.1516394112. Epub 2015 Nov 2.

27.

Application of genome editing technologies to the study and treatment of hematological disease.

Pellagatti A, Dolatshad H, Yip BH, Valletta S, Boultwood J.

Adv Biol Regul. 2016 Jan;60:122-134. doi: 10.1016/j.jbior.2015.09.005. Epub 2015 Sep 26. Review.

PMID:
26433620
28.

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, Przychodzen B, Sahgal N, Kanapin AA, Lockstone H, Scifo L, Vandenberghe P, Papaemmanuil E, Smith CW, Campbell PJ, Ogawa S, Maciejewski JP, Cazzola M, Savage KI, Boultwood J.

Leukemia. 2015 Aug;29(8):1798. doi: 10.1038/leu.2015.178. No abstract available.

29.

PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.

Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U.

Blood. 2015 Aug 27;126(9):1118-27. doi: 10.1182/blood-2014-12-618801. Epub 2015 Jul 13.

30.

Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.

Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y.

Br J Haematol. 2016 Apr;173(1):161-5. doi: 10.1111/bjh.13574. Epub 2015 Jun 24. No abstract available.

31.

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q).

Bello E, Pellagatti A, Shaw J, Mecucci C, Kušec R, Killick S, Giagounidis A, Raynaud S, Calasanz MJ, Fenaux P, Boultwood J.

Br J Haematol. 2015 Oct;171(2):210-214. doi: 10.1111/bjh.13563. Epub 2015 Jun 18.

32.

Recent Advances in the 5q- Syndrome.

Pellagatti A, Boultwood J.

Mediterr J Hematol Infect Dis. 2015 May 20;7(1):e2015037. doi: 10.4084/MJHID.2015.037. eCollection 2015. Review.

33.

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

Pellagatti A, Roy S, Di Genua C, Burns A, McGraw K, Valletta S, Larrayoz MJ, Fernandez-Mercado M, Mason J, Killick S, Mecucci C, Calasanz MJ, List A, Schuh A, Boultwood J.

Leukemia. 2016 Jan;30(1):247-50. doi: 10.1038/leu.2015.129. Epub 2015 May 20. No abstract available.

34.

Application of CRISPR/Cas9 genome editing to the study and treatment of disease.

Pellagatti A, Dolatshad H, Valletta S, Boultwood J.

Arch Toxicol. 2015 Jul;89(7):1023-34. doi: 10.1007/s00204-015-1504-y. Epub 2015 Apr 1. Review.

PMID:
25827103
35.

IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.

Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will B, Wei S, Steidl U, Verma A.

Blood. 2015 May 14;125(20):3144-52. doi: 10.1182/blood-2015-01-621631. Epub 2015 Mar 25. Erratum in: Blood. 2015 Jul 16;126(3):425. Barreryo, Laura [corrected to Barreyro, Laura].

36.

The molecular pathogenesis of the myelodysplastic syndromes.

Pellagatti A, Boultwood J.

Eur J Haematol. 2015 Jul;95(1):3-15. doi: 10.1111/ejh.12515. Epub 2015 Feb 20. Review.

PMID:
25645650
37.

Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.

Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J.

Nat Commun. 2015 Jan 9;6:5901. doi: 10.1038/ncomms6901.

38.

Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells.

Dolatshad H, Pellagatti A, Fernandez-Mercado M, Yip BH, Malcovati L, Attwood M, Przychodzen B, Sahgal N, Kanapin AA, Lockstone H, Scifo L, Vandenberghe P, Papaemmanuil E, Smith CW, Campbell PJ, Ogawa S, Maciejewski JP, Cazzola M, Savage KI, Boultwood J.

Leukemia. 2015 May;29(5):1092-103. doi: 10.1038/leu.2014.331. Epub 2014 Nov 27. Erratum in: Leukemia. 2015 Aug;29(8):1798. Leukemia. 2015 Aug;29(8):1798.

39.

Recurrent ETNK1 mutations in atypical chronic myeloid leukemia.

Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Fontana D, Spinelli R, Magistroni V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Usala E, Kim DW, Rea D, Zervakis K, Viniou N, Symeonidis A, Becker H, Boultwood J, Campiotti L, Carrabba M, Elli E, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Piazza R.

Blood. 2015 Jan 15;125(3):499-503. doi: 10.1182/blood-2014-06-579466. Epub 2014 Oct 24.

40.

Reduced translation of GATA1 in Diamond-Blackfan anemia.

Boultwood J, Pellagatti A.

Nat Med. 2014 Jul;20(7):703-4. doi: 10.1038/nm.3630. No abstract available.

PMID:
24999938
41.

Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) MDS.

Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P.

Blood. 2014 Jul 31;124(5):780-90. doi: 10.1182/blood-2014-01-552463. Epub 2014 Jun 2.

42.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Woll PS, Kjällquist U, Chowdhury O, Doolittle H, Wedge DC, Thongjuea S, Erlandsson R, Ngara M, Anderson K, Deng Q, Mead AJ, Stenson L, Giustacchini A, Duarte S, Giannoulatou E, Taylor S, Karimi M, Scharenberg C, Mortera-Blanco T, Macaulay IC, Clark SA, Dybedal I, Josefsen D, Fenaux P, Hokland P, Holm MS, Cazzola M, Malcovati L, Tauro S, Bowen D, Boultwood J, Pellagatti A, Pimanda JE, Unnikrishnan A, Vyas P, Göhring G, Schlegelberger B, Tobiasson M, Kvalheim G, Constantinescu SN, Nerlov C, Nilsson L, Campbell PJ, Sandberg R, Papaemmanuil E, Hellström-Lindberg E, Linnarsson S, Jacobsen SE.

Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15. Erratum in: Cancer Cell. 2015 Apr 13;27(4):603-5. Cancer Cell. 2014 Jun 16;25(6):861.

43.

PRPF8 defects cause missplicing in myeloid malignancies.

Kurtovic-Kozaric A, Przychodzen B, Singh J, Konarska MM, Clemente MJ, Otrock ZK, Nakashima M, Hsi ED, Yoshida K, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Boultwood J, Makishima H, Maciejewski JP, Padgett RA.

Leukemia. 2015 Jan;29(1):126-36. doi: 10.1038/leu.2014.144. Epub 2014 Apr 30.

44.

Identification of a BRCA1-mRNA splicing complex required for efficient DNA repair and maintenance of genomic stability.

Savage KI, Gorski JJ, Barros EM, Irwin GW, Manti L, Powell AJ, Pellagatti A, Lukashchuk N, McCance DJ, McCluggage WG, Schettino G, Salto-Tellez M, Boultwood J, Richard DJ, McDade SS, Harkin DP.

Mol Cell. 2014 May 8;54(3):445-59. doi: 10.1016/j.molcel.2014.03.021. Epub 2014 Apr 17.

45.

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.

Pellagatti A, Fernandez-Mercado M, Di Genua C, Larrayoz MJ, Killick S, Dolatshad H, Burns A, Calasanz MJ, Schuh A, Boultwood J.

Leukemia. 2014 May;28(5):1148-51. doi: 10.1038/leu.2013.381. Epub 2013 Dec 24. No abstract available.

PMID:
24365791
46.

The role of splicing factor mutations in the pathogenesis of the myelodysplastic syndromes.

Boultwood J, Dolatshad H, Varanasi SS, Yip BH, Pellagatti A.

Adv Biol Regul. 2014 Jan;54:153-61. doi: 10.1016/j.jbior.2013.09.005. Epub 2013 Sep 15. Review.

PMID:
24080589
47.

TP53 suppression promotes erythropoiesis in del(5q) MDS, suggesting a targeted therapeutic strategy in lenalidomide-resistant patients.

Caceres G, McGraw K, Yip BH, Pellagatti A, Johnson J, Zhang L, Liu K, Zhang LM, Fulp WJ, Lee JH, Al Ali NH, Basiorka A, Smith LJ, Daugherty FJ, Littleton N, Wells RA, Sokol L, Wei S, Komrokji RS, Boultwood J, List AF.

Proc Natl Acad Sci U S A. 2013 Oct 1;110(40):16127-32. doi: 10.1073/pnas.1311055110. Epub 2013 Sep 16.

48.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.

49.

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.

Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, McDonald EJ, Killick S, Hellström-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J.

J Clin Oncol. 2013 Oct 1;31(28):3557-64. doi: 10.1200/JCO.2012.45.5626. Epub 2013 Sep 3.

PMID:
24002510
50.

Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Fernandez-Mercado M, Pellagatti A, Di Genua C, Larrayoz MJ, Winkelmann N, Aranaz P, Burns A, Schuh A, Calasanz MJ, Cross NC, Boultwood J.

Br J Haematol. 2013 Oct;163(2):235-9. doi: 10.1111/bjh.12491. Epub 2013 Jul 24.

PMID:
23889083

Supplemental Content

Loading ...
Support Center